Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed

Next Previous
Trial Profile

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabotegravir+rilpivirine (Primary) ; Cabotegravir; Cabotegravir; Rilpivirine; Rilpivirine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-2M
  • Sponsors ViiV Healthcare

    • Most Recent Events

    • 22 Dec 2023 Results of post-hoc analysis cabotegravir plus rilpivirine long-acting results by baseline body mass index (BMI) category among patients from FLAIR, ATLAS, and ATLAS-2 M trials pooled through Week (W) 48, published in the Journal of Infectious Diseases.
    • 18 Aug 2023 Planned End Date changed from 7 Feb 2024 to 31 Dec 2026.
    • 22 Feb 2023 Results of sub study(n=118) assessing Safety, tolerability, participant-reported outcomes, and efficacy of thigh injections of cabotegravir+Rilpivirine in Virally Suppressed Adults with Hiv-1 presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top